
zzso and zzso zzso zzso zzso are clinically active as single agents and zzso zzso This phase I, zzso trial evaluated the maximum tolerated dose zzso and safety of zzso followed by zzso in patients with breast or zzso zzso 

Using 3 + 3 dose zzso zzso of zzso patients received escalating doses of zzso zzso zzso on days 1 and 15 and zzso zzso zzso on day 1 of a zzso zzso All patients received zzso acid and vitamin zzso until 21 days after last zzso zzso Patients continued until zzso toxicity zzso or progression zzso 

From zzso to zzso 29 patients entered zzso median age: zzso years zzso zzso zzso zzso zzso zzso primary disease zzso zzso zzso breast zzso zzso zzso prior zzso chemotherapy zzso surgery zzso zzso zzso and radiation zzso zzso dose zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso and zzso zzso zzso zzso zzso zzso zzso grade zzso zzso zzso zzso zzso zzso zzso zzso anemia zzso zzso inflammation zzso zzso zzso zzso zzso syndrome zzso zzso zzso zzso for zzso zzso zzso toxicity zzso patient request zzso and investigator request zzso 

5 zzso patients zzso achieved partial zzso median time to progression zzso was zzso months zzso zzso 

zzso plus zzso was reasonably tolerated in this zzso zzso zzso zzso 500 zzso and zzso 40 zzso may be carried forward to phase II studies in specific patient zzso zzso in zzso zzso patients was greater than zzso 

